AstraZeneca said net profit increased in the fourth quarter as a rise in proceeds from licensing deals offset sharply lower sales of the company’s top-selling cholesterol pill, after several cheap generic versions launched earlier this year.
from WSJ.com: US Business http://ift.tt/2kYFSxg
via IFTTT
No comments:
Post a Comment